An Open-Label Study of YM087 (Conivaptan) in Patients With Euvolemic or Hypervolemic Hyponatremia
A 4-day, Open-Label, Multicenter Phase 3b Study of IV YM087 in Patients With Euvolemic or Hypervolemic Hyponatremia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Afula, Israel
-
Ashkelon, Israel
-
Hadera, Israel
-
Haifa, Israel
- 2 Sites
-
Holon, Israel
-
Jerusalem, Israel
- 2 Sites
-
Nahariya, Israel
-
Rechovot, Israel
-
Safed, Israel
- 2 Sites
-
Tel-Aviv, Israel
-
Zerifin, Israel
-
-
-
-
-
Amanzimototi, South Africa
-
Bellville, South Africa
-
Bloemfontein, South Africa
-
Durban, South Africa
- 2 Sites
-
Johannesburg, South Africa
- 4 Sites
-
Krugersdorp, South Africa
-
Lyttelton, South Africa
-
Pretoria, South Africa
-
Somerset West, South Africa
-
Soweto, South Africa
-
-
-
-
Arizona
-
Tuscon, Arizona, United States, 85723
-
-
Colorado
-
Denver, Colorado, United States, 80262
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20007
-
-
Georgia
-
Augusta, Georgia, United States, 30901
-
-
Michigan
-
Petoskey, Michigan, United States, 49700
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
-
-
South Carolina
-
Columbia, South Carolina, United States, 29209
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Serum sodium levels less than or equal 130mEq/L
- Euvolemic or Hypervolemic hyponatremia
Exclusion Criteria:
- Clinical evidence of volume depletion or dehydration
- Untreated severe hypothyroidism, hyperthyroidism, or adrenal insufficiency
- Uncontrolled brady-or tachyarrhythmias requiring pacemaker placement or treatment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: 1
Lower dose
|
IV
Other Names:
|
|
Experimental: 2
Higher dose
|
IV
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Baseline-adjusted change in AUC for serum sodium
Time Frame: 96 Hours
|
96 Hours
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Comparison of safety between patients in each study arm
Time Frame: 96 Hours
|
96 Hours
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Art Wheeler, MD, Cumberland Pharmaceuticals, Inc.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 087-CL-080
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.